KOD

Kodiak Sciences Inc.

Healthcare
Biotechnology
$2.06B market cap

Forecast run · Sep 16, 2026Upside rank 719 of 3,149

Model Signal

ForecastQ Daily Probabilities

45.8%

35.6%

39.3%

Analyst Consensus

Recommendation2.33/5 Buy

Last price$32.89

Price target$63.75

Implied move+93.8%

Analysts18

ForecastQ Portfolios

KOD is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.